Global Vaccine Conjugate research

Vaccine Conjugate Comprehensive Study by Type (Monovalent, Multivalent, Others), Application (Influenza, Meningococcal, Pneumococcal, Others), Pathogen Type (Bacterial Conjugate Vaccine, Viral Conjugate Vaccine, Combination (Viral and Bacterial) Conjugate Vaccine), Patient Stage (Pediatrics Conjugate Vaccine, Adults Conjugate Vaccine), Disease (Pneumococcal, Influenza, DTP, Meningococcal, Others) Players and Region - Global Market Outlook to 2026

Vaccine Conjugate Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Vaccine Conjugate Market Overview:
Conjugate vaccines refer to those vaccines that contain bacterial capsule polysaccharide or conjugated to a protein or the antigen attached. This protein plays a vital role in enhancing the immunogenic property of the polysaccharide which helps to protect the body from microorganisms.

Growth Drivers
  • Rising Prevalence Of Diseases
  • Increasing Use Of Conjugate Vaccines For Adults To Prevent Disease Caused By Microorganisms
  • Growing Awareness About Conjugate Vaccine and Its Advantages

Roadblocks
  • Complex Production Procedure Of Conjugate Vaccine
  • Low Accessibility To Vaccines In Remote Areas

Opportunities
  • Emerging Economies Such As India And China Present An Array Of Opportunities For This Market
  • Research & Development of New Vaccines

Challenges
  • Lack Of Skilled Professionals


Competitive Landscape:

Some of the key players profiled in the report are Bharat Biotech (India), Biological E (India), CSL Limited (Australia), GlaxoSmithKline, plc. (U.K.), Merck and Company (U.S.), Neuron Biotech (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi Pasteur (France) and Serum Institute of India (India). Additionally, following companies can also be profiled that are part of our coverage like SutroVax Inc., Fablife and Sinovac Biotech Ltd.. Analyst at AMA Research see United States Players to retain maximum share of Global Vaccine Conjugate market by 2026. Considering Market by Pathogen Type, the sub-segment i.e. Bacterial Conjugate Vaccine will boost the Vaccine Conjugate market. Considering Market by Patient Stage, the sub-segment i.e. Pediatrics Conjugate Vaccine will boost the Vaccine Conjugate market. Considering Market by Disease , the sub-segment i.e. Pneumococcal will boost the Vaccine Conjugate market.

According to the U.S. National Library of Medicine, National Institutes of Health, the highest mortality cases reported were due to vaccine-preventable diseases. High-income countries accounting for 87% of the population of have pneumococcal conjugate vaccines in their immunization schedules, whereas only 2% had pneumococcal conjugate vaccines in their immunization schedules among the total population of low-income countries

What Can be Explored with the Vaccine Conjugate Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Vaccine Conjugate Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Vaccine Conjugate
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Vaccine Conjugate market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Vaccine Conjugate market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Traders, Distributors, and Suppliers, Manufacturers, Government and Regional Agencies, Research Organizations, Consultants and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Monovalent
  • Multivalent
  • Others
By Application
  • Influenza
  • Meningococcal
  • Pneumococcal
  • Others
By Pathogen Type
  • Bacterial Conjugate Vaccine
  • Viral Conjugate Vaccine
  • Combination (Viral and Bacterial) Conjugate Vaccine

By Patient Stage
  • Pediatrics Conjugate Vaccine
  • Adults Conjugate Vaccine

By Disease
  • Pneumococcal
  • Influenza
  • DTP
  • Meningococcal
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence Of Diseases
      • 3.2.2. Increasing Use Of Conjugate Vaccines For Adults To Prevent Disease Caused By Microorganisms
      • 3.2.3. Growing Awareness About Conjugate Vaccine and Its Advantages
    • 3.3. Market Challenges
      • 3.3.1. Lack Of Skilled Professionals
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Vaccine Conjugate, by Type, Application, Pathogen Type, Patient Stage, Disease and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Vaccine Conjugate (Value)
      • 5.2.1. Global Vaccine Conjugate by: Type (Value)
        • 5.2.1.1. Monovalent
        • 5.2.1.2. Multivalent
        • 5.2.1.3. Others
      • 5.2.2. Global Vaccine Conjugate by: Application (Value)
        • 5.2.2.1. Influenza
        • 5.2.2.2. Meningococcal
        • 5.2.2.3. Pneumococcal
        • 5.2.2.4. Others
      • 5.2.3. Global Vaccine Conjugate by: Pathogen Type (Value)
        • 5.2.3.1. Bacterial Conjugate Vaccine
        • 5.2.3.2. Viral Conjugate Vaccine
        • 5.2.3.3. Combination (Viral and Bacterial) Conjugate Vaccine
      • 5.2.4. Global Vaccine Conjugate by: Patient Stage (Value)
        • 5.2.4.1. Pediatrics Conjugate Vaccine
        • 5.2.4.2. Adults Conjugate Vaccine
      • 5.2.5. Global Vaccine Conjugate Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Vaccine Conjugate (Volume)
      • 5.3.1. Global Vaccine Conjugate by: Type (Volume)
        • 5.3.1.1. Monovalent
        • 5.3.1.2. Multivalent
        • 5.3.1.3. Others
      • 5.3.2. Global Vaccine Conjugate by: Application (Volume)
        • 5.3.2.1. Influenza
        • 5.3.2.2. Meningococcal
        • 5.3.2.3. Pneumococcal
        • 5.3.2.4. Others
      • 5.3.3. Global Vaccine Conjugate by: Pathogen Type (Volume)
        • 5.3.3.1. Bacterial Conjugate Vaccine
        • 5.3.3.2. Viral Conjugate Vaccine
        • 5.3.3.3. Combination (Viral and Bacterial) Conjugate Vaccine
      • 5.3.4. Global Vaccine Conjugate by: Patient Stage (Volume)
        • 5.3.4.1. Pediatrics Conjugate Vaccine
        • 5.3.4.2. Adults Conjugate Vaccine
      • 5.3.5. Global Vaccine Conjugate Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Vaccine Conjugate (Price)
      • 5.4.1. Global Vaccine Conjugate by: Type (Price)
  • 6. Vaccine Conjugate: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bharat Biotech (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Biological E (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. CSL Limited (Australia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline, plc. (U.K.)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck and Company (U.S.)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Neuron Biotech (U.S.)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer, Inc. (U.S.)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi Pasteur (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Serum Institute of India (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Vaccine Conjugate Sale, by Type, Application, Pathogen Type, Patient Stage, Disease and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Vaccine Conjugate (Value)
      • 7.2.1. Global Vaccine Conjugate by: Type (Value)
        • 7.2.1.1. Monovalent
        • 7.2.1.2. Multivalent
        • 7.2.1.3. Others
      • 7.2.2. Global Vaccine Conjugate by: Application (Value)
        • 7.2.2.1. Influenza
        • 7.2.2.2. Meningococcal
        • 7.2.2.3. Pneumococcal
        • 7.2.2.4. Others
      • 7.2.3. Global Vaccine Conjugate by: Pathogen Type (Value)
        • 7.2.3.1. Bacterial Conjugate Vaccine
        • 7.2.3.2. Viral Conjugate Vaccine
        • 7.2.3.3. Combination (Viral and Bacterial) Conjugate Vaccine
      • 7.2.4. Global Vaccine Conjugate by: Patient Stage (Value)
        • 7.2.4.1. Pediatrics Conjugate Vaccine
        • 7.2.4.2. Adults Conjugate Vaccine
      • 7.2.5. Global Vaccine Conjugate Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Vaccine Conjugate (Volume)
      • 7.3.1. Global Vaccine Conjugate by: Type (Volume)
        • 7.3.1.1. Monovalent
        • 7.3.1.2. Multivalent
        • 7.3.1.3. Others
      • 7.3.2. Global Vaccine Conjugate by: Application (Volume)
        • 7.3.2.1. Influenza
        • 7.3.2.2. Meningococcal
        • 7.3.2.3. Pneumococcal
        • 7.3.2.4. Others
      • 7.3.3. Global Vaccine Conjugate by: Pathogen Type (Volume)
        • 7.3.3.1. Bacterial Conjugate Vaccine
        • 7.3.3.2. Viral Conjugate Vaccine
        • 7.3.3.3. Combination (Viral and Bacterial) Conjugate Vaccine
      • 7.3.4. Global Vaccine Conjugate by: Patient Stage (Volume)
        • 7.3.4.1. Pediatrics Conjugate Vaccine
        • 7.3.4.2. Adults Conjugate Vaccine
      • 7.3.5. Global Vaccine Conjugate Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Vaccine Conjugate (Price)
      • 7.4.1. Global Vaccine Conjugate by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Vaccine Conjugate: by Type(USD Million)
  • Table 2. Vaccine Conjugate Monovalent , by Region USD Million (2015-2020)
  • Table 3. Vaccine Conjugate Multivalent , by Region USD Million (2015-2020)
  • Table 4. Vaccine Conjugate Others , by Region USD Million (2015-2020)
  • Table 5. Vaccine Conjugate: by Application(USD Million)
  • Table 6. Vaccine Conjugate Influenza , by Region USD Million (2015-2020)
  • Table 7. Vaccine Conjugate Meningococcal , by Region USD Million (2015-2020)
  • Table 8. Vaccine Conjugate Pneumococcal , by Region USD Million (2015-2020)
  • Table 9. Vaccine Conjugate Others , by Region USD Million (2015-2020)
  • Table 10. Vaccine Conjugate: by Pathogen Type(USD Million)
  • Table 11. Vaccine Conjugate Bacterial Conjugate Vaccine , by Region USD Million (2015-2020)
  • Table 12. Vaccine Conjugate Viral Conjugate Vaccine , by Region USD Million (2015-2020)
  • Table 13. Vaccine Conjugate Combination (Viral and Bacterial) Conjugate Vaccine , by Region USD Million (2015-2020)
  • Table 14. Vaccine Conjugate: by Patient Stage(USD Million)
  • Table 15. Vaccine Conjugate Pediatrics Conjugate Vaccine , by Region USD Million (2015-2020)
  • Table 16. Vaccine Conjugate Adults Conjugate Vaccine , by Region USD Million (2015-2020)
  • Table 17. South America Vaccine Conjugate, by Country USD Million (2015-2020)
  • Table 18. South America Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 19. South America Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 20. South America Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 21. South America Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 22. South America Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 23. Brazil Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 24. Brazil Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 25. Brazil Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 26. Brazil Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 27. Brazil Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 28. Argentina Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 29. Argentina Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 30. Argentina Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 31. Argentina Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 32. Argentina Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 33. Rest of South America Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 34. Rest of South America Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 35. Rest of South America Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 36. Rest of South America Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 37. Rest of South America Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 38. Asia Pacific Vaccine Conjugate, by Country USD Million (2015-2020)
  • Table 39. Asia Pacific Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 40. Asia Pacific Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 41. Asia Pacific Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 42. Asia Pacific Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 43. Asia Pacific Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 44. China Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 45. China Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 46. China Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 47. China Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 48. China Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 49. Japan Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 50. Japan Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 51. Japan Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 52. Japan Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 53. Japan Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 54. India Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 55. India Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 56. India Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 57. India Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 58. India Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 59. South Korea Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 60. South Korea Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 61. South Korea Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 62. South Korea Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 63. South Korea Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 64. Taiwan Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 65. Taiwan Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 66. Taiwan Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 67. Taiwan Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 68. Taiwan Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 69. Australia Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 70. Australia Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 71. Australia Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 72. Australia Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 73. Australia Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 74. Rest of Asia-Pacific Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 75. Rest of Asia-Pacific Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 76. Rest of Asia-Pacific Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 77. Rest of Asia-Pacific Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 78. Rest of Asia-Pacific Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 79. Europe Vaccine Conjugate, by Country USD Million (2015-2020)
  • Table 80. Europe Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 81. Europe Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 82. Europe Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 83. Europe Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 84. Europe Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 85. Germany Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 86. Germany Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 87. Germany Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 88. Germany Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 89. Germany Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 90. France Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 91. France Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 92. France Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 93. France Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 94. France Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 95. Italy Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 96. Italy Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 97. Italy Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 98. Italy Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 99. Italy Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 100. United Kingdom Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 101. United Kingdom Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 102. United Kingdom Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 103. United Kingdom Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 104. United Kingdom Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 105. Netherlands Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 106. Netherlands Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 107. Netherlands Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 108. Netherlands Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 109. Netherlands Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 110. Rest of Europe Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 111. Rest of Europe Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 112. Rest of Europe Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 113. Rest of Europe Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 114. Rest of Europe Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 115. MEA Vaccine Conjugate, by Country USD Million (2015-2020)
  • Table 116. MEA Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 117. MEA Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 118. MEA Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 119. MEA Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 120. MEA Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 121. Middle East Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 122. Middle East Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 123. Middle East Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 124. Middle East Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 125. Middle East Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 126. Africa Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 127. Africa Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 128. Africa Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 129. Africa Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 130. Africa Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 131. North America Vaccine Conjugate, by Country USD Million (2015-2020)
  • Table 132. North America Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 133. North America Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 134. North America Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 135. North America Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 136. North America Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 137. United States Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 138. United States Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 139. United States Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 140. United States Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 141. United States Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 142. Canada Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 143. Canada Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 144. Canada Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 145. Canada Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 146. Canada Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 147. Mexico Vaccine Conjugate, by Type USD Million (2015-2020)
  • Table 148. Mexico Vaccine Conjugate, by Application USD Million (2015-2020)
  • Table 149. Mexico Vaccine Conjugate, by Pathogen Type USD Million (2015-2020)
  • Table 150. Mexico Vaccine Conjugate, by Patient Stage USD Million (2015-2020)
  • Table 151. Mexico Vaccine Conjugate, by Disease USD Million (2015-2020)
  • Table 152. Vaccine Conjugate Sales: by Type(K Unit)
  • Table 153. Vaccine Conjugate Sales Monovalent , by Region K Unit (2015-2020)
  • Table 154. Vaccine Conjugate Sales Multivalent , by Region K Unit (2015-2020)
  • Table 155. Vaccine Conjugate Sales Others , by Region K Unit (2015-2020)
  • Table 156. Vaccine Conjugate Sales: by Application(K Unit)
  • Table 157. Vaccine Conjugate Sales Influenza , by Region K Unit (2015-2020)
  • Table 158. Vaccine Conjugate Sales Meningococcal , by Region K Unit (2015-2020)
  • Table 159. Vaccine Conjugate Sales Pneumococcal , by Region K Unit (2015-2020)
  • Table 160. Vaccine Conjugate Sales Others , by Region K Unit (2015-2020)
  • Table 161. Vaccine Conjugate Sales: by Pathogen Type(K Unit)
  • Table 162. Vaccine Conjugate Sales Bacterial Conjugate Vaccine , by Region K Unit (2015-2020)
  • Table 163. Vaccine Conjugate Sales Viral Conjugate Vaccine , by Region K Unit (2015-2020)
  • Table 164. Vaccine Conjugate Sales Combination (Viral and Bacterial) Conjugate Vaccine , by Region K Unit (2015-2020)
  • Table 165. Vaccine Conjugate Sales: by Patient Stage(K Unit)
  • Table 166. Vaccine Conjugate Sales Pediatrics Conjugate Vaccine , by Region K Unit (2015-2020)
  • Table 167. Vaccine Conjugate Sales Adults Conjugate Vaccine , by Region K Unit (2015-2020)
  • Table 168. South America Vaccine Conjugate Sales, by Country K Unit (2015-2020)
  • Table 169. South America Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 170. South America Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 171. South America Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 172. South America Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 173. South America Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 174. Brazil Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 175. Brazil Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 176. Brazil Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 177. Brazil Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 178. Brazil Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 179. Argentina Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 180. Argentina Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 181. Argentina Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 182. Argentina Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 183. Argentina Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 184. Rest of South America Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 185. Rest of South America Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 186. Rest of South America Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 187. Rest of South America Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 188. Rest of South America Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 189. Asia Pacific Vaccine Conjugate Sales, by Country K Unit (2015-2020)
  • Table 190. Asia Pacific Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 191. Asia Pacific Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 192. Asia Pacific Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 193. Asia Pacific Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 194. Asia Pacific Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 195. China Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 196. China Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 197. China Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 198. China Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 199. China Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 200. Japan Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 201. Japan Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 202. Japan Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 203. Japan Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 204. Japan Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 205. India Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 206. India Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 207. India Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 208. India Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 209. India Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 210. South Korea Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 211. South Korea Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 212. South Korea Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 213. South Korea Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 214. South Korea Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 215. Taiwan Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 216. Taiwan Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 217. Taiwan Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 218. Taiwan Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 219. Taiwan Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 220. Australia Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 221. Australia Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 222. Australia Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 223. Australia Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 224. Australia Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 225. Rest of Asia-Pacific Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 226. Rest of Asia-Pacific Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 227. Rest of Asia-Pacific Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 228. Rest of Asia-Pacific Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 229. Rest of Asia-Pacific Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 230. Europe Vaccine Conjugate Sales, by Country K Unit (2015-2020)
  • Table 231. Europe Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 232. Europe Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 233. Europe Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 234. Europe Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 235. Europe Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 236. Germany Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 237. Germany Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 238. Germany Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 239. Germany Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 240. Germany Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 241. France Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 242. France Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 243. France Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 244. France Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 245. France Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 246. Italy Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 247. Italy Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 248. Italy Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 249. Italy Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 250. Italy Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 251. United Kingdom Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 252. United Kingdom Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 253. United Kingdom Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 254. United Kingdom Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 255. United Kingdom Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 256. Netherlands Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 257. Netherlands Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 258. Netherlands Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 259. Netherlands Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 260. Netherlands Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 261. Rest of Europe Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 262. Rest of Europe Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 263. Rest of Europe Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 264. Rest of Europe Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 265. Rest of Europe Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 266. MEA Vaccine Conjugate Sales, by Country K Unit (2015-2020)
  • Table 267. MEA Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 268. MEA Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 269. MEA Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 270. MEA Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 271. MEA Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 272. Middle East Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 273. Middle East Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 274. Middle East Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 275. Middle East Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 276. Middle East Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 277. Africa Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 278. Africa Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 279. Africa Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 280. Africa Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 281. Africa Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 282. North America Vaccine Conjugate Sales, by Country K Unit (2015-2020)
  • Table 283. North America Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 284. North America Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 285. North America Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 286. North America Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 287. North America Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 288. United States Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 289. United States Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 290. United States Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 291. United States Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 292. United States Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 293. Canada Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 294. Canada Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 295. Canada Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 296. Canada Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 297. Canada Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 298. Mexico Vaccine Conjugate Sales, by Type K Unit (2015-2020)
  • Table 299. Mexico Vaccine Conjugate Sales, by Application K Unit (2015-2020)
  • Table 300. Mexico Vaccine Conjugate Sales, by Pathogen Type K Unit (2015-2020)
  • Table 301. Mexico Vaccine Conjugate Sales, by Patient Stage K Unit (2015-2020)
  • Table 302. Mexico Vaccine Conjugate Sales, by Disease K Unit (2015-2020)
  • Table 303. Vaccine Conjugate: by Type(USD/Units)
  • Table 304. Company Basic Information, Sales Area and Its Competitors
  • Table 305. Company Basic Information, Sales Area and Its Competitors
  • Table 306. Company Basic Information, Sales Area and Its Competitors
  • Table 307. Company Basic Information, Sales Area and Its Competitors
  • Table 308. Company Basic Information, Sales Area and Its Competitors
  • Table 309. Company Basic Information, Sales Area and Its Competitors
  • Table 310. Company Basic Information, Sales Area and Its Competitors
  • Table 311. Company Basic Information, Sales Area and Its Competitors
  • Table 312. Company Basic Information, Sales Area and Its Competitors
  • Table 313. Company Basic Information, Sales Area and Its Competitors
  • Table 314. Vaccine Conjugate: by Type(USD Million)
  • Table 315. Vaccine Conjugate Monovalent , by Region USD Million (2021-2026)
  • Table 316. Vaccine Conjugate Multivalent , by Region USD Million (2021-2026)
  • Table 317. Vaccine Conjugate Others , by Region USD Million (2021-2026)
  • Table 318. Vaccine Conjugate: by Application(USD Million)
  • Table 319. Vaccine Conjugate Influenza , by Region USD Million (2021-2026)
  • Table 320. Vaccine Conjugate Meningococcal , by Region USD Million (2021-2026)
  • Table 321. Vaccine Conjugate Pneumococcal , by Region USD Million (2021-2026)
  • Table 322. Vaccine Conjugate Others , by Region USD Million (2021-2026)
  • Table 323. Vaccine Conjugate: by Pathogen Type(USD Million)
  • Table 324. Vaccine Conjugate Bacterial Conjugate Vaccine , by Region USD Million (2021-2026)
  • Table 325. Vaccine Conjugate Viral Conjugate Vaccine , by Region USD Million (2021-2026)
  • Table 326. Vaccine Conjugate Combination (Viral and Bacterial) Conjugate Vaccine , by Region USD Million (2021-2026)
  • Table 327. Vaccine Conjugate: by Patient Stage(USD Million)
  • Table 328. Vaccine Conjugate Pediatrics Conjugate Vaccine , by Region USD Million (2021-2026)
  • Table 329. Vaccine Conjugate Adults Conjugate Vaccine , by Region USD Million (2021-2026)
  • Table 330. South America Vaccine Conjugate, by Country USD Million (2021-2026)
  • Table 331. South America Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 332. South America Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 333. South America Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 334. South America Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 335. South America Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 336. Brazil Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 337. Brazil Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 338. Brazil Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 339. Brazil Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 340. Brazil Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 341. Argentina Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 342. Argentina Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 343. Argentina Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 344. Argentina Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 345. Argentina Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 346. Rest of South America Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 347. Rest of South America Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 348. Rest of South America Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 349. Rest of South America Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 350. Rest of South America Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 351. Asia Pacific Vaccine Conjugate, by Country USD Million (2021-2026)
  • Table 352. Asia Pacific Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 353. Asia Pacific Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 354. Asia Pacific Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 355. Asia Pacific Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 356. Asia Pacific Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 357. China Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 358. China Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 359. China Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 360. China Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 361. China Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 362. Japan Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 363. Japan Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 364. Japan Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 365. Japan Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 366. Japan Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 367. India Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 368. India Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 369. India Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 370. India Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 371. India Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 372. South Korea Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 373. South Korea Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 374. South Korea Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 375. South Korea Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 376. South Korea Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 377. Taiwan Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 378. Taiwan Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 379. Taiwan Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 380. Taiwan Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 381. Taiwan Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 382. Australia Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 383. Australia Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 384. Australia Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 385. Australia Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 386. Australia Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 387. Rest of Asia-Pacific Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 388. Rest of Asia-Pacific Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 389. Rest of Asia-Pacific Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 390. Rest of Asia-Pacific Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 391. Rest of Asia-Pacific Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 392. Europe Vaccine Conjugate, by Country USD Million (2021-2026)
  • Table 393. Europe Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 394. Europe Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 395. Europe Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 396. Europe Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 397. Europe Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 398. Germany Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 399. Germany Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 400. Germany Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 401. Germany Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 402. Germany Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 403. France Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 404. France Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 405. France Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 406. France Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 407. France Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 408. Italy Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 409. Italy Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 410. Italy Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 411. Italy Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 412. Italy Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 413. United Kingdom Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 414. United Kingdom Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 415. United Kingdom Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 416. United Kingdom Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 417. United Kingdom Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 418. Netherlands Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 419. Netherlands Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 420. Netherlands Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 421. Netherlands Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 422. Netherlands Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 423. Rest of Europe Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 424. Rest of Europe Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 425. Rest of Europe Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 426. Rest of Europe Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 427. Rest of Europe Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 428. MEA Vaccine Conjugate, by Country USD Million (2021-2026)
  • Table 429. MEA Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 430. MEA Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 431. MEA Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 432. MEA Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 433. MEA Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 434. Middle East Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 435. Middle East Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 436. Middle East Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 437. Middle East Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 438. Middle East Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 439. Africa Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 440. Africa Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 441. Africa Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 442. Africa Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 443. Africa Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 444. North America Vaccine Conjugate, by Country USD Million (2021-2026)
  • Table 445. North America Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 446. North America Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 447. North America Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 448. North America Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 449. North America Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 450. United States Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 451. United States Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 452. United States Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 453. United States Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 454. United States Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 455. Canada Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 456. Canada Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 457. Canada Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 458. Canada Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 459. Canada Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 460. Mexico Vaccine Conjugate, by Type USD Million (2021-2026)
  • Table 461. Mexico Vaccine Conjugate, by Application USD Million (2021-2026)
  • Table 462. Mexico Vaccine Conjugate, by Pathogen Type USD Million (2021-2026)
  • Table 463. Mexico Vaccine Conjugate, by Patient Stage USD Million (2021-2026)
  • Table 464. Mexico Vaccine Conjugate, by Disease USD Million (2021-2026)
  • Table 465. Vaccine Conjugate Sales: by Type(K Unit)
  • Table 466. Vaccine Conjugate Sales Monovalent , by Region K Unit (2021-2026)
  • Table 467. Vaccine Conjugate Sales Multivalent , by Region K Unit (2021-2026)
  • Table 468. Vaccine Conjugate Sales Others , by Region K Unit (2021-2026)
  • Table 469. Vaccine Conjugate Sales: by Application(K Unit)
  • Table 470. Vaccine Conjugate Sales Influenza , by Region K Unit (2021-2026)
  • Table 471. Vaccine Conjugate Sales Meningococcal , by Region K Unit (2021-2026)
  • Table 472. Vaccine Conjugate Sales Pneumococcal , by Region K Unit (2021-2026)
  • Table 473. Vaccine Conjugate Sales Others , by Region K Unit (2021-2026)
  • Table 474. Vaccine Conjugate Sales: by Pathogen Type(K Unit)
  • Table 475. Vaccine Conjugate Sales Bacterial Conjugate Vaccine , by Region K Unit (2021-2026)
  • Table 476. Vaccine Conjugate Sales Viral Conjugate Vaccine , by Region K Unit (2021-2026)
  • Table 477. Vaccine Conjugate Sales Combination (Viral and Bacterial) Conjugate Vaccine , by Region K Unit (2021-2026)
  • Table 478. Vaccine Conjugate Sales: by Patient Stage(K Unit)
  • Table 479. Vaccine Conjugate Sales Pediatrics Conjugate Vaccine , by Region K Unit (2021-2026)
  • Table 480. Vaccine Conjugate Sales Adults Conjugate Vaccine , by Region K Unit (2021-2026)
  • Table 481. South America Vaccine Conjugate Sales, by Country K Unit (2021-2026)
  • Table 482. South America Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 483. South America Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 484. South America Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 485. South America Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 486. South America Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 487. Brazil Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 488. Brazil Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 489. Brazil Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 490. Brazil Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 491. Brazil Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 492. Argentina Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 493. Argentina Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 494. Argentina Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 495. Argentina Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 496. Argentina Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 497. Rest of South America Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 498. Rest of South America Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 499. Rest of South America Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 500. Rest of South America Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 501. Rest of South America Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 502. Asia Pacific Vaccine Conjugate Sales, by Country K Unit (2021-2026)
  • Table 503. Asia Pacific Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 504. Asia Pacific Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 505. Asia Pacific Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 506. Asia Pacific Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 507. Asia Pacific Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 508. China Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 509. China Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 510. China Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 511. China Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 512. China Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 513. Japan Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 514. Japan Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 515. Japan Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 516. Japan Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 517. Japan Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 518. India Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 519. India Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 520. India Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 521. India Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 522. India Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 523. South Korea Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 524. South Korea Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 525. South Korea Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 526. South Korea Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 527. South Korea Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 528. Taiwan Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 529. Taiwan Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 530. Taiwan Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 531. Taiwan Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 532. Taiwan Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 533. Australia Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 534. Australia Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 535. Australia Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 536. Australia Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 537. Australia Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 538. Rest of Asia-Pacific Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 539. Rest of Asia-Pacific Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 540. Rest of Asia-Pacific Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 541. Rest of Asia-Pacific Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 542. Rest of Asia-Pacific Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 543. Europe Vaccine Conjugate Sales, by Country K Unit (2021-2026)
  • Table 544. Europe Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 545. Europe Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 546. Europe Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 547. Europe Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 548. Europe Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 549. Germany Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 550. Germany Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 551. Germany Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 552. Germany Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 553. Germany Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 554. France Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 555. France Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 556. France Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 557. France Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 558. France Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 559. Italy Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 560. Italy Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 561. Italy Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 562. Italy Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 563. Italy Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 564. United Kingdom Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 565. United Kingdom Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 566. United Kingdom Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 567. United Kingdom Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 568. United Kingdom Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 569. Netherlands Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 570. Netherlands Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 571. Netherlands Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 572. Netherlands Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 573. Netherlands Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 574. Rest of Europe Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 575. Rest of Europe Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 576. Rest of Europe Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 577. Rest of Europe Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 578. Rest of Europe Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 579. MEA Vaccine Conjugate Sales, by Country K Unit (2021-2026)
  • Table 580. MEA Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 581. MEA Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 582. MEA Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 583. MEA Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 584. MEA Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 585. Middle East Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 586. Middle East Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 587. Middle East Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 588. Middle East Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 589. Middle East Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 590. Africa Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 591. Africa Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 592. Africa Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 593. Africa Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 594. Africa Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 595. North America Vaccine Conjugate Sales, by Country K Unit (2021-2026)
  • Table 596. North America Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 597. North America Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 598. North America Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 599. North America Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 600. North America Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 601. United States Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 602. United States Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 603. United States Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 604. United States Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 605. United States Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 606. Canada Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 607. Canada Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 608. Canada Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 609. Canada Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 610. Canada Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 611. Mexico Vaccine Conjugate Sales, by Type K Unit (2021-2026)
  • Table 612. Mexico Vaccine Conjugate Sales, by Application K Unit (2021-2026)
  • Table 613. Mexico Vaccine Conjugate Sales, by Pathogen Type K Unit (2021-2026)
  • Table 614. Mexico Vaccine Conjugate Sales, by Patient Stage K Unit (2021-2026)
  • Table 615. Mexico Vaccine Conjugate Sales, by Disease K Unit (2021-2026)
  • Table 616. Vaccine Conjugate: by Type(USD/Units)
  • Table 617. Research Programs/Design for This Report
  • Table 618. Key Data Information from Secondary Sources
  • Table 619. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Vaccine Conjugate: by Type USD Million (2015-2020)
  • Figure 5. Global Vaccine Conjugate: by Application USD Million (2015-2020)
  • Figure 6. Global Vaccine Conjugate: by Pathogen Type USD Million (2015-2020)
  • Figure 7. Global Vaccine Conjugate: by Patient Stage USD Million (2015-2020)
  • Figure 8. South America Vaccine Conjugate Share (%), by Country
  • Figure 9. Asia Pacific Vaccine Conjugate Share (%), by Country
  • Figure 10. Europe Vaccine Conjugate Share (%), by Country
  • Figure 11. MEA Vaccine Conjugate Share (%), by Country
  • Figure 12. North America Vaccine Conjugate Share (%), by Country
  • Figure 13. Global Vaccine Conjugate: by Type K Unit (2015-2020)
  • Figure 14. Global Vaccine Conjugate: by Application K Unit (2015-2020)
  • Figure 15. Global Vaccine Conjugate: by Pathogen Type K Unit (2015-2020)
  • Figure 16. Global Vaccine Conjugate: by Patient Stage K Unit (2015-2020)
  • Figure 17. South America Vaccine Conjugate Share (%), by Country
  • Figure 18. Asia Pacific Vaccine Conjugate Share (%), by Country
  • Figure 19. Europe Vaccine Conjugate Share (%), by Country
  • Figure 20. MEA Vaccine Conjugate Share (%), by Country
  • Figure 21. North America Vaccine Conjugate Share (%), by Country
  • Figure 22. Global Vaccine Conjugate: by Type USD/Units (2015-2020)
  • Figure 23. Global Vaccine Conjugate share by Players 2020 (%)
  • Figure 24. Global Vaccine Conjugate share by Players (Top 3) 2020(%)
  • Figure 25. Global Vaccine Conjugate share by Players (Top 5) 2020(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Bharat Biotech (India) Revenue, Net Income and Gross profit
  • Figure 28. Bharat Biotech (India) Revenue: by Geography 2020
  • Figure 29. Biological E (India) Revenue, Net Income and Gross profit
  • Figure 30. Biological E (India) Revenue: by Geography 2020
  • Figure 31. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 32. CSL Limited (Australia) Revenue: by Geography 2020
  • Figure 33. GlaxoSmithKline, plc. (U.K.) Revenue, Net Income and Gross profit
  • Figure 34. GlaxoSmithKline, plc. (U.K.) Revenue: by Geography 2020
  • Figure 35. Merck and Company (U.S.) Revenue, Net Income and Gross profit
  • Figure 36. Merck and Company (U.S.) Revenue: by Geography 2020
  • Figure 37. Neuron Biotech (U.S.) Revenue, Net Income and Gross profit
  • Figure 38. Neuron Biotech (U.S.) Revenue: by Geography 2020
  • Figure 39. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 40. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 41. Pfizer, Inc. (U.S.) Revenue, Net Income and Gross profit
  • Figure 42. Pfizer, Inc. (U.S.) Revenue: by Geography 2020
  • Figure 43. Sanofi Pasteur (France) Revenue, Net Income and Gross profit
  • Figure 44. Sanofi Pasteur (France) Revenue: by Geography 2020
  • Figure 45. Serum Institute of India (India) Revenue, Net Income and Gross profit
  • Figure 46. Serum Institute of India (India) Revenue: by Geography 2020
  • Figure 47. Global Vaccine Conjugate: by Type USD Million (2021-2026)
  • Figure 48. Global Vaccine Conjugate: by Application USD Million (2021-2026)
  • Figure 49. Global Vaccine Conjugate: by Pathogen Type USD Million (2021-2026)
  • Figure 50. Global Vaccine Conjugate: by Patient Stage USD Million (2021-2026)
  • Figure 51. South America Vaccine Conjugate Share (%), by Country
  • Figure 52. Asia Pacific Vaccine Conjugate Share (%), by Country
  • Figure 53. Europe Vaccine Conjugate Share (%), by Country
  • Figure 54. MEA Vaccine Conjugate Share (%), by Country
  • Figure 55. North America Vaccine Conjugate Share (%), by Country
  • Figure 56. Global Vaccine Conjugate: by Type K Unit (2021-2026)
  • Figure 57. Global Vaccine Conjugate: by Application K Unit (2021-2026)
  • Figure 58. Global Vaccine Conjugate: by Pathogen Type K Unit (2021-2026)
  • Figure 59. Global Vaccine Conjugate: by Patient Stage K Unit (2021-2026)
  • Figure 60. South America Vaccine Conjugate Share (%), by Country
  • Figure 61. Asia Pacific Vaccine Conjugate Share (%), by Country
  • Figure 62. Europe Vaccine Conjugate Share (%), by Country
  • Figure 63. MEA Vaccine Conjugate Share (%), by Country
  • Figure 64. North America Vaccine Conjugate Share (%), by Country
  • Figure 65. Global Vaccine Conjugate: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Bharat Biotech (India)
  • Biological E (India)
  • CSL Limited (Australia)
  • GlaxoSmithKline, plc. (U.K.)
  • Merck and Company (U.S.)
  • Neuron Biotech (U.S.)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (U.S.)
  • Sanofi Pasteur (France)
  • Serum Institute of India (India)
Additional players considered in the study are as follows:
SutroVax Inc. , Fablife , Sinovac Biotech Ltd.
Select User Access Type

Key Highlights of Report


Jan 2022 237 Pages 88 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Vaccine Conjugate research Quantitative research analysis
Global Vaccine Conjugate research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Vaccine Conjugate market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Vaccine Conjugate market are Bharat Biotech (India), Biological E (India), CSL Limited (Australia), GlaxoSmithKline, plc. (U.K.), Merck and Company (U.S.), Neuron Biotech (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi Pasteur (France) and Serum Institute of India (India), to name a few.

Know More About Global Vaccine Conjugate research Report?

Have a Query? Click Here

Other Related Reports

Eye Health Supplements Comprehensive Study by Distribution Channel (Online Retailing, Pharmacies/Drug Stores, Health & Beauty Stores, Others), Form (Tablet, Capsule, Others), Ingredient (Lutein and...
$ 3750
Bioelectric Medicine Comprehensive Study by Type (Implantable Cardioverter-Defibrillators, Spinal Cord Stimulators, Cochlear Implants, Deep Brain Stimulators, Vagus Nerve Stimulators, Transcutaneous ...
$ 3750
Root Canal Files Comprehensive Study by Type (Stainless Steel, Ni-Ti Alloy, Other), Application (Hospitals, Dental Clinics), Distribution Channel (Online, Offline) Players and Region - Global Market ...
$ 3500
Medical Mouthwash Comprehensive Study by Type (Fluoride Mouthwashes, Cosmetic Mouthwashes, Antiseptic Mouthwashes, Natural Mouthwashes, Total Care Mouthwashes), Application (Household, Commercial Use...
$ 3650
Pharmaceutical Logistics Comprehensive Study by Type (Cold Chain Logistics, Non-cold Chain Logistics), Application (Bio Pharma, Chemical Pharma, Specially Pharma), Service (Logistics, Procedures), S...
$ 3350
Specialty Drug Distribution Comprehensive Study by Application (Retail, Home Health, Clinics, Pharmacies), Drug Type (Oncology Drugs, Rheumatoid Arthritis Drugs, Multiple Sclerosis Drugs, Hemophilia ...
$ 3450